Phenobarbital Antibody (401): sc-57970

Phenobarbital Antibody (401) is a mouse monoclonal IgG1 antibody that detects Phenobarbital protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). Anti-Phenobarbital antibody (401) is available as a non-conjugated format, providing researchers with a reliable tool for studying this important compound. Phenobarbital, a barbiturate, is recognized as the most widely used and oldest anticonvulsant globally, serving as a first-line treatment for neonatal seizures. Phenobarbital′s efficacy in seizure control is comparable to that of Phenytoin and carbamazepine; however, Phenobarbital is associated with more severe side effects, including dizziness, nystagmus, and ataxia. Phenobarbital plays a crucial role in the central and peripheral nervous systems, where Phenobarbital exerts depressant effects, making Phenobarbital vital for managing seizure disorders. Understanding the pharmacokinetics of Phenobarbital is essential, as Phenobarbital is primarily metabolized in the liver through hydroxylation and glucuronidation, with renal excretion being the main route of elimination. With a molecular weight of 232.235 g/mol and a half-life ranging from 53 to 118 hours, Phenobarbital′s prolonged action necessitates careful monitoring to avoid overdose, which can lead to significant slowing of bodily functions. Anti-Phenobarbital antibody (401) enables researchers to gain insights into the therapeutic and adverse effects of this critical anticonvulsant.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Phenobarbital Antibody (401) References:

1. Anticonvulsant and neurotoxic effects of intracerebroventricular injection of phenytoin, phenobarbital and carbamazepine in an amygdala-kindling model of epilepsy in the rat.  |  Barcia, JA., et al. 1999. Epilepsy Res. 33: 159-67. PMID: 10094427
2. Phenobarbital compared with phenytoin for the treatment of neonatal seizures.  |  Painter, MJ., et al. 1999. N Engl J Med. 341: 485-9. PMID: 10441604
3. Three-month follow-up of shoulder-hand syndrome induced by phenobarbital and treated with gabapentin.  |  Rovetta, G., et al. 2001. Int J Tissue React. 23: 39-43. PMID: 11392062
4. Conventional anticonvulsant drugs in the guinea pig kindling model of partial seizures: effects of acute phenobarbital, valproate, and ethosuximide.  |  Gilbert, TH., et al. 2002. Exp Brain Res. 146: 336-44. PMID: 12232690
5. Nicotine therapy in adulthood reverses the synaptic and behavioral deficits elicited by prenatal exposure to phenobarbital.  |  Beer, A., et al. 2005. Neuropsychopharmacology. 30: 156-65. PMID: 15496940
6. Primidone/phenobarbital-induced periodic alternating nystagmus.  |  Schwankhaus, JD., et al. 1989. Ann Ophthalmol. 21: 230-2. PMID: 2764437
7. Efficacy of phenobarbital in neonatal seizures.  |  Van Orman, CB. and Darwish, HZ. 1985. Can J Neurol Sci. 12: 95-9. PMID: 4016597
8. Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique.  |  Robinson, GM., et al. 1981. Clin Pharmacol Ther. 30: 71-6. PMID: 7237901
9. Dosage programming of phenobarbital in neonatal seizures.  |  Alonso Gonzalez, AC., et al. 1993. J Clin Pharm Ther. 18: 267-70. PMID: 8227234